Companies Like Lexeo Therapeutics (NASDAQ:LXEO) Are In A Position To Invest In Growth
Lexeo Therapeutics Initiated at Outperform by Baird
Lexeo Therapeutics Initiated at Outperform by Baird
Express News | Lexeo Therapeutics Inc : Baird Initiates Coverage With Outperform Rating; Price Target $28
Lexeo Therapeutics(LXEO.US) Officer Sells US$88,263.82 in Common Stock
$Lexeo Therapeutics(LXEO.US)$ Officer Townsend Richard Nolan sold 5,000 shares of common stock on Jun 10, 2024 at an average price of $17.65 for a total value of $88,263.82.Source: Announcement What i
Baird Initiates Lexeo Therapeutics(LXEO.US) With Buy Rating, Announces Target Price $28
Baird analyst Brian Skorney initiates coverage on $Lexeo Therapeutics(LXEO.US)$ with a buy rating, and sets the target price at $28.According to TipRanks data, the analyst has a success rate of 41.1%
Lexeo Therapeutics Initiated at Buy by HC Wainwright & Co.
Lexeo Therapeutics Initiated at Buy by HC Wainwright & Co.
Lexeo Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/06/2024 28.65% HC Wainwright & Co. → $22 Initiates Coverage On → Buy 03/12/2024 40.35% RBC Capital $22
H.C. Wainwright Initiates Lexeo Therapeutics(LXEO.US) With Buy Rating, Announces Target Price $22
H.C. Wainwright analyst Mitchell Kapoor initiates coverage on $Lexeo Therapeutics(LXEO.US)$ with a buy rating, and sets the target price at $22.According to TipRanks data, the analyst has a success ra
Express News | Lexeo Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $22
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Krystal Biotech (KRYS) and Veeva Systems (VEEV)
Lexeo Therapeutics(LXEO.US) Officer Sells US$66,093 in Common Stock
$Lexeo Therapeutics(LXEO.US)$ Officer Townsend Richard Nolan sold 5,000 shares of common stock on May 13, 2024 at an average price of $13.2186 for a total value of $66,093.Source: Announcement What is
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), RAPT Therapeutics (RAPT) and Hookipa Pharma (HOOK)
RBC Capital Remains a Buy on Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics | 10-Q: Quarterly report
Express News | Lexeo Therapeutics Inc: Qtrly Net Loss Was $21.7 Mln or $0.77 per Share
Lexeo Therapeutics 1Q Research and Developement Expenses $15.7M >LXEO
Lexeo Therapeutics 1Q Research and Developement Expenses $15.7M >LXEO
Lexeo Therapeutics 1Q Loss/Shr 77c >LXEO
Lexeo Therapeutics 1Q Loss/Shr 77c >LXEO
Express News | Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and
Buy Rating Affirmed for Lexeo Therapeutics Amid Strategic Cornell Collaboration and Promising Therapy Advancements
No Data